Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single-dose Administration of IBI3013 in Healthy Adult Trial Participants and Multiple-dose Administration in Active Non-segmental Vitiligo Trial Participants and Severe Alopecia Areata Trial Participants - a Randomized, Double-blind, Placebo-controlled, Dose-escalation Study
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Participants (registry)
- 160
- Start
- April 2026
- Primary completion
- December 2027 (planned)
- Study completion
- December 2028 (planned)
- Last registry update
- April 2026
- Countries
- China
Conditions studied: Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata
Interventions: placebo, Baricitinib tablets, IBI3013
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.